Autoimmunity reviews最新文献

{"title":"Extracellular vesicles in inflammatory bowel disease: from immune regulation and barrier repair to precise transformation.","authors":"Yiyi Lv, Qian Yang, Xixi Cai, Gang Chen, Shaoyun Wang","doi":"10.1016/j.autrev.2026.104170","DOIUrl":"10.1016/j.autrev.2026.104170","url":null,"abstract":"<p><p>Extracellular vesicles (EVs) have been shown to be key regulators of intestinal homeostasis and inflammatory responses, offering new insights into the pathogenesis of inflammatory bowel disease (IBD) and the development of targeted therapeutic strategies. EVs in the intestine can be secreted by intestinal epithelial cells (IECs), mesenchymal stem cells (MSCs), immune cell subsets, the gut microbiota, and even dietary sources. Its vesicle internal load contains a variety of biologically active molecules, including proteins, miRNAs, and microbial signals, which mediate immune regulation, intestinal barrier repair, and microbiota regulation. Mechanistically, EVs shape intestinal immune homeostasis by regulating T cell differentiation, macrophage polarization, inflammasome activation and epithelial regeneration, while promoting angiogenesis and fibrosis reversal, and mediating interaction between the host and the microbiota. In clinical settings, EVs are stable and easily accessible biomarkers in blood, feces, and intestinal lavage fluid, which can reflect disease activity, microbiota disorders, and treatment responses. The therapeutic value of EVs lies in their cell targeting ability, stability and drug-loading potential, enabling them to be transformed from biological entities into medical tools. Although it still faces challenges in large-scale production, biodistribution and regulatory standardization, it has broad prospects in promoting the accurate diagnosis and treatment of IBD.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104170"},"PeriodicalIF":9.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions aimed at advancing gender equity in rheumatology: Insights from the Coalition for Health and Gender Equity (CHANGE) survey.","authors":"Latika Gupta, Lekshmi Minikumari Rahulan, Taanya Talreja, Pavel Ovseiko, Laure Gossec, Manali Sarkar, Jessica Day, Lisa Traboco, Anne Marie Russell, Syed Atiqul Haq, Catherine L Hill, Dzifa Dey, Neelam Hassan, Alejandra Magdalena Babini, Ana Maria Arredondo Gonzalez, Carlos Enrique Toro Gutiérrez, Christina Duftner, Deshiré Alpizar-Rodríguez, Humeira Badsha, Elena Nikiphorou, Ghita Harifi, Ihsane Hmamouchi, Joan Von Feldt, Júlia Boechat Farani, Asgar Ali Kalla, Laura Andreoli, Mariana Peixoto Souza, Lai-Shan Tam, Penélope Esther Palominos, Ran Nakashima, Yoshiya Tanaka, Wilson Bautista-Molano, Vikas Agarwal, Nelly Ziade, Grace Wright, Laura C Coates","doi":"10.1016/j.autrev.2026.104172","DOIUrl":"10.1016/j.autrev.2026.104172","url":null,"abstract":"<p><strong>Background: </strong>Gender disparities in rheumatology persist despite increasing female representation. This comprehensive global survey, conducted by the Coalition for Health and Gender Equity (CHANGE) group, examined preferences for gender equity interventions among rheumatology professionals.</p><p><strong>Methods: </strong>A cross-sectional online survey of rheumatologists and allied health professionals was conducted across 105 countries (January 2023-May 2024). Intervention preferences spanned four domains: conference-based, organizational, skills training, and work-based strategies. Gender differences were evaluated using logistic regression adjusted for years of work experience, with subgroup analyses by Human Development Index (HDI), Gender Inequality Index (GII), professional role, and caregiving responsibilities. Multiple comparisons were adjusted using Benjamini- Hochberg correction for false discovery rate.</p><p><strong>Results: </strong>Among 1945 respondents (66.4% female), the most widely endorsed interventions overall were family- and child-friendly conference policies (71.4%), communication and scientific writing training (52.6%), and engagement of national rheumatology groups (46.9%). Women demonstrated significantly stronger support for increasing the visibility of female role models (11.89% vs 5.81%, OR = 3.29, p < 0.01), establishing gender-balanced committees (17.66% vs 16.01%, OR = 1.76, p < 0.01), and gender-sensitive editorial board policies (12.70% vs 10.66%, OR = 1.77, p < 0.01). Respondents from higher-GII countries prioritised scientific writing masterclasses (OR = 4.58, p < 0.05) and career planning training (OR = 3.90, p < 0.05) but showed lower endorsement of unconscious bias training (OR = 0.48, p < 0.05) and male allyship programmes (OR = 0.42, p < 0.05). Women in low/middle-HDI countries more frequently selected grant writing support (40.3% vs 26.4%, p < 0.01).</p><p><strong>Conclusion: </strong>Gender equity intervention preferences vary systematically across contexts. These findings provide empirical foundations for developing culturally responsive, evidence-informed intervention frameworks to advance gender equity in rheumatology.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104172"},"PeriodicalIF":9.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological personalization of JAK inhibitors in rheumatoid arthritis: A multi-omics and AI-based scoping review and evidence-gap map.","authors":"Tatiana Bobkova, Artem Bobkov","doi":"10.1016/j.autrev.2026.104173","DOIUrl":"10.1016/j.autrev.2026.104173","url":null,"abstract":"<p><strong>Introduction: </strong>Personalization of Janus kinase inhibitor (JAKi) therapy in rheumatoid arthritis (RA) remains an unresolved clinical task. Multi-omics/multimodal (MO/MM) data and artificial intelligence/machine learning (AI/ML) may support treatment-response prediction, but their JAKi-specific application has not been systematically mapped.</p><p><strong>Methods: </strong>We conducted a JBI scoping review with PRISMA-ScR reporting; the protocol was registered on OSF. Major bibliographic databases and additional sources were searched through 7 July 2025 without language or publication-status restrictions. We included direct JAKi studies using AI/ML or integrated MO/MM data and contextual non-JAKi RA studies combining MO/MM with AI/ML. Risk of bias and reporting completeness were assessed using PROBAST+AI and TRIPOD+AI. Findings were synthesized narratively.</p><p><strong>Results: </strong>Eighteen publications were included, four of which were conference abstracts. The corpus comprised three direct JAKi AI/ML studies, three JAKi-associated MO/MM studies without AI/ML, eleven contextual non-JAKi AI/ML studies, and one mixed JAKi/TNFi study. AI/ML was applied in 15/18 publications. None of the direct JAKi AI/ML studies performed independent external validation. Reported AUROCs ranged from 0.656 to 1.00, with the highest estimates arising under internal or incompletely reported validation. Calibration and explainability were infrequently reported.</p><p><strong>Conclusion: </strong>Direct evidence for AI/ML-guided JAKi personalization remains sparse and heterogeneous and does not support selection of a specific JAKi or routine individualized treatment decisions. Progress requires adequately powered JAKi-specific cohorts, class-separated analyses, harmonized measurements, transparent preprocessing, and independent external validation. The \"data × methods × JAKi\" map identifies both emerging signals and the links that must be strengthened before MO/MM and AI/ML can support clinical decision-making in RA.</p><p><strong>Take-home message: </strong>Current multi-omics and AI/ML evidence is insufficient to guide routine selection of a specific JAK inhibitor in rheumatoid arthritis. Independent external validation, calibration, and prospective assessment of clinical utility are required before these approaches can support treatment decisions.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104173"},"PeriodicalIF":9.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The renaissance of hydroxychloroquine: bridging antimicrobial immunity and autoimmunity in rheumatic diseases.","authors":"Márk Szabó, András Perl, György Nagy, Judit Majnik","doi":"10.1016/j.autrev.2026.104175","DOIUrl":"10.1016/j.autrev.2026.104175","url":null,"abstract":"<p><p>Hydroxychloroquine (HCQ) has been a cornerstone of rheumatic disease therapy for more than half a century. Its best-established immunomodulatory actions arise from endosomal and lysosomal alkalinization, with inhibition of endosomal Toll-like receptor 7/9 signaling and attenuation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) activation. Apart from these well-established mechanisms we also discuss a proposed model in which HCQ might influence CD3ζ/CD4 endocytic turnover. A structured narrative search of PubMed/MEDLINE, Scopus, and Web of Science was performed between July and November 2025. Clinically, HCQ remains foundational in systemic lupus erythematosus (SLE), whereas evidence for antiphospholipid syndrome, primary Sjögren's syndrome, lichen planus, and chronic spontaneous urticaria is limited and does not support routine use outside selected off-label settings. Randomized trials demonstrated no clinical benefit in COVID-19. Retinopathy remains the principal dose- and duration-dependent toxicity. Limiting the daily dose to ≤5 mg/kg actual body weight and following current ophthalmic screening recommendations are the main preventive measures. HCQ blood-level monitoring may support adherence assessment and exposure-informed care, but therapeutic thresholds and laboratory interpretation are not yet universally standardized. This review integrates mechanistic, clinical, and safety evidence while explicitly distinguishing established findings from hypotheses and lower-certainty observations.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104175"},"PeriodicalIF":9.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-DFS70 antibodies in systemic lupus erythematosus and lupus nephritis: revisiting their clinical implications.","authors":"Federica Zucca, Valeria Longoni, Dionysis Nikolopoulos, Denis Lagutkin, Natalia Sherina, Lorenzo Beretta, Konstantinos Triantafyllias, Christopher Sjöwall, Ioannis Parodis","doi":"10.1016/j.autrev.2026.104174","DOIUrl":"10.1016/j.autrev.2026.104174","url":null,"abstract":"<p><p>Antibodies against the Dense Fine Speckled 70 kDa protein (anti-DFS70), associated with the anti-cell 2 (AC-2) pattern on immunofluorescence HEp-2 cells, represent a frequent finding in antinuclear antibody (ANA) testing, particularly among healthy individuals, and have been proposed as an exclusion marker for systemic autoimmune rheumatic diseases (SARDs). In systemic lupus erythematosus (SLE), however, their interpretation is more complex. Anti-DFS70 antibodies are uncommon, rarely monospecific, and are not consistently associated with global disease activity, although selective associations with musculoskeletal and mucocutaneous manifestations have been reported. In lupus nephritis (LN), evidence from a single dedicated cohort suggests that anti-DFS70 antibodies are enriched compared with healthy controls and patients with non-lupus chronic kidney disease (CKD), while within biopsy-proven LN they may associate with proliferative histological subtypes and intrarenal inflammatory activity. In this narrative review, we provide a critical overview of the epidemiological, serological, clinical, and experimental evidence on anti-DFS70 antibodies, with a particular focus on SLE and LN. Overall, current evidence supports a context-dependent interpretation of anti-DFS70 antibodies across health, systemic autoimmunity, and organ-specific inflammation.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104174"},"PeriodicalIF":9.8,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The placebo effect in psoriatic arthritis.","authors":"Francesca Motta, Carlo Cannistrà, Antonio Tonutti, Carlo Selmi","doi":"10.1016/j.autrev.2026.104171","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104171","url":null,"abstract":"<p><p>The placebo effect represents a clinically relevant and underexplored phenomenon in modern medicine with significant implications for treatments, particularly in rheumatological conditions, as placebo groups in clinical trial commonly achieve some degree of subjective and objective response, with an unclear correlation from the routine clinical observations. Emerging evidence highlights that the placebo effect extends beyond symptom perception, modulating markers of inflammation through neuroimmune pathways; however, these mechanisms remain poorly understood. In psoriatic arthritis (PsA), the placebo effect is of particular relevance, given the heterogeneous disease manifestations, the frequent neuropsychiatric disturbances, and the relevance of non-inflammatory or nociplastic pain. We herein provide a narrative review of the placebo responses observed in PsA clinical studies, the methodological challenges in isolating real drug effects, particularly in terms of allowed or background medications. We also emphasize the role of the placebo response in PsA and the broad aspects of the disease that influence the perception of pain in those patients, such as the physician and patient expectations, metabolic comorbidities and socio-economic background. A deeper understanding and systematic integration of placebo metrics and contextual determinants into future studies will be essential to accurately interpret drug efficacy and optimize trial methodology in this most heterogeneous disease.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104171"},"PeriodicalIF":9.8,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions.","authors":"Pakeeran Siriratnam, Mineesh Datta, Katherine Buzzard, Robb Wesselingh, Wei Yeh, Nabil Seery, Michael Zhong, Anna He, Vilija Jokubaitis, Tissa Wijeratne, Olga Skibina, Helmut Butzkueven, Saif Huda, Anneke Van der Walt, Mastura Monif","doi":"10.1016/j.autrev.2026.104169","DOIUrl":"10.1016/j.autrev.2026.104169","url":null,"abstract":"<p><p>The diagnosis and treatment of multiple sclerosis (MS) remain an evolving challenge in modern neurology. Recent advances are reflected in the 2024 revision of the McDonald criteria, which aim to facilitate earlier, more accurate and biologically informed diagnosis of MS. Key updates include expansion of dissemination in space to incorporate the optic nerve, integration of relapsing and progressive onset MS within a unified diagnostic framework, provision for diagnosis in selected asymptomatic individuals, dispensing with the requirement for dissemination of time in certain situations and incorporation of more specific imaging biomarkers. These include specific radiological features such as the central vein sign and paramagnetic rim lesions, visual pathway assessments using optical coherence tomography, magnetic resonance imaging and visual evoked potentials. Furthermore, oligoclonal bands and kappa free light chain index are now acknowledged as alternative cerebrospinal fluid biomarkers of intrathecal immunoglobulin synthesis. These revisions acknowledge the evolving understanding of MS biology alongside the substantial advances in disease modifying therapies. This review uses the 2024 McDonald criteria as an overarching framework to synthesise and contextualise the recent developments in MS diagnosis and treatment, highlighting their clinical implications, current limitations and future directions.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104169"},"PeriodicalIF":9.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgA vasculitis sibling clustering: From HLA-DRB1 genetic burden to nephritis risk stratification","authors":"Lingjia Ren ,&nbsp;Xu Yan ,&nbsp;Xia Zhang ,&nbsp;Xu Jixiang ,&nbsp;Miao Jiang ,&nbsp;Xianqing Ren ,&nbsp;Ying Ding","doi":"10.1016/j.autrev.2026.104110","DOIUrl":"10.1016/j.autrev.2026.104110","url":null,"abstract":"<div><div>IgA vasculitis (IgAV) is the most common systemic small-vessel vasculitis in childhood, with an annual incidence of 3 to 26.7 per 100,000 children. Although it is predominantly sporadic, its 1.9% familial clustering rate and significant tendency for sibling comorbidity suggest a non-random pathogenesis. Multicohort GWAS data confirm that HLA-DRB1*01 and HLA-DRB1*11 are common genetic risk loci across ethnic groups. Furthermore, the core pathogenic molecule, galactose-deficient IgA1 (Gd-IgA1), exhibits a heritability of up to 64% in affected families, constituting the intrinsic basis for sibling concordance. Regarding the triggering mechanism, approximately 75% of IgAV cases are preceded by upper respiratory or gastrointestinal prodromal infections; the cross-transmission of streptococci and viruses within the family environment provides the external trigger for sibling-to-sibling transmission. Clinical phenotypes show that familial cases exhibit high consistency in the pattern of target organ involvement, and the renal involvement in the index case has significant predictive value for stratifying sibling risk. This article proposes potential mechanisms underlying the synchronized onset of disease and the formation of phenotypic mirroring among siblings, aiming to establish a clinical system for early warning and precise intervention based on family history.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"25 8","pages":"Article 104110"},"PeriodicalIF":8.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Meta-analysis of meteorological conditions and rheumatoid arthritis”","authors":"Feng Luo ,&nbsp;Xueming Yao ,&nbsp;Wukai Ma","doi":"10.1016/j.autrev.2026.104006","DOIUrl":"10.1016/j.autrev.2026.104006","url":null,"abstract":"<div><div>This correspondence addresses critical methodological limitations in the recent meta analysis by Hu et al. regarding meteorological conditions and rheumatoid arthritis (RA). We highlight issues of clinical heterogeneity arising from the conflation of disparate outcomes and inconsistent follow-up durations. Furthermore, we identify a “quality score paradox” where small-sample studies are disproportionately rated as high-quality compared to large-scale evidence. Finally, we argue that pooling data across incompatible climatic zones neglects the effect of baseline adaptation, and we suggest that the observed association between atmospheric pressure and joint swelling supports a hydraulic physical mechanism distinct from immune-mediated inflammatory flares.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"25 3","pages":"Article 104006"},"PeriodicalIF":8.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiopathic pericarditis in 2025: Advances in diagnosis and therapeutic strategies","authors":"Martin Michaud ,&nbsp;Yvan Jamilloux ,&nbsp;Clément Delmas ,&nbsp;Olivier Lairez ,&nbsp;Hélène Coulier ,&nbsp;Eric Bruguière ,&nbsp;Grégory Pugnet","doi":"10.1016/j.autrev.2026.103991","DOIUrl":"10.1016/j.autrev.2026.103991","url":null,"abstract":"<div><div>Idiopathic acute pericarditis is the most frequent form of acute pericarditis in Western countries. Although the short-term course of an uncomplicated first episode is often benign, a substantial proportion of patients progress to complicated forms with recurrences, incessant disease, or chronic constriction, leading to impaired quality of life and challenging management. In 2025, updated American and European guidelines for the diagnosis and management of pericarditis were issued, refining diagnostic criteria—particularly the role of C-reactive protein and multimodality imaging—and integrating targeted therapies such as interleukin-1 (IL-1) inhibitors. A structured assessment of risk factors for complications helps identify patients who require closer monitoring or hospitalization. Initial treatment combines non-steroidal anti-inflammatory drugs or aspirin and colchicine; in case of intolerance or resistance, second-line options include systemic corticosteroids or pharmacological blockade of IL-1. While the long-term prognosis of acute idiopathic pericarditis is generally good in terms of survival and low rates of constrictive pericarditis, recurrent and incessant forms are associated with significant morbidity. Individualized, risk-adapted management and prolonged follow-up are therefore recommended. This review summarizes contemporary data on the pathophysiology, diagnosis, management, and outcomes of idiopathic pericarditis, with a focus on autoinflammatory mechanisms and IL-1–targeted therapies.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"25 3","pages":"Article 103991"},"PeriodicalIF":8.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}